Review Article

Circulating MicroRNAs for Diagnosis of Acute Pulmonary Embolism: Still a Long Way to Go

Matteo Sobrero,¹ Fabrizio Montecucco,¹,² and Federico Carbone,¹,²

¹First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 Viale Benedetto XV, 16132 Genoa, Italy
²IRCCS Ospedale Policlinico San Martino, Genoa-Italian Cardiovascular Network, 10 Largo Benzi, 16132 Genoa, Italy

Correspondence should be addressed to Fabrizio Montecucco; fabrizio.montecucco@unige.it

Received 11 June 2021; Revised 14 December 2021; Accepted 30 December 2021; Published 10 January 2022

Academic Editor: Dobrin Vassilev

Copyright © 2022 Matteo Sobrero et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Venous thromboembolism (VTE) represents the third most frequent cause of acute cardiovascular syndrome. Among VTE, acute pulmonary embolism (APE) is the most life-threatening complication. Due to the low specificity of symptoms clinical diagnosis of APE may be sometimes very difficult. Accordingly, the latest European guidelines only suggest clinical prediction tests for diagnosis of APE, eventually associated with D-dimer, a biomarker burdened by a very low specificity. A growing body of evidence is highlighting the role of miRNAs in hemostasis and thrombosis. Due to their partial inheritance and susceptibility to the environmental factors, miRNAs are increasingly described as active modifiers of the classical Virchow’s triad. Clinical evidence on deep venous thrombosis reported specific miRNA signatures associated to thrombosis development, organization, recanalization, and resolution. Conversely, data of miRNA profiling as a predictor/diagnostic marker of APE are still preliminary. Here, we have summarized clinical evidence on the potential role of miRNA in diagnosis of APE. Despite some intriguing insight, miRNA assay is still far from any potential clinical application. Especially, the small sample size of cohorts likely represents the major limitation of published studies, so that extensive analysis of miRNA profiles with a machine learning approach are warranted in the next future. In addition, the cost-benefit ratio of miRNA assay still has a negative impact on their clinical application and routinely test.

1. Introduction

Venous thromboembolism (VTE) is a family of disease that includes deep venous thrombosis (DVT) and acute pulmonary embolism (APE). VTE is commonly found in clinical practice being the third cause of acute cardiovascular syndrome after myocardial infarction and stroke [1]. Among this class of disease, APE represents the most serious complication of VTE thus requiring early diagnosis and treatment. The incidence of APE ranges from about 39 to 115 per 100,000 population every year and accounts for about 300,000 death/year in US [2]. A recent increased in its incidence was also observed during SARS-CoV-2 outbreak, likely as an expression of the thromboinflammatory storm triggered by infection [3]. Symptoms of APE are often not specific—ranging from mild symptoms to sudden death—and clinical diagnosis may be sometimes very difficult [4]. Pulmonary angiography and computed tomography pulmonary angiography (CTPA) are highly specific for diagnosis of APE [5], but they require intravenous contrast infusion that may represents a great concern in patients with chronic kidney failure or allergic diathesis. Latest European guidelines published in 2019 have included two major prediction tests for APE diagnosis: the revised Geneva rule and the Wells score [6]. Their goal is to increase the rate of APE diagnosis, by stratifying patients across risk categories. Nevertheless, for only 65% of patients categorized at high-risk APE is finally diagnosed. The search for biomarkers able to implement the diagnostic chart—alone or combined with clinical scores—then represents an urgent clinical need. D-dimer assay offers high sensitivity but low specificity, thus limiting its application as exclusion test for diagnosis of APE [7, 8]. Here, we summarize the role of microRNAs (miRNAs) in VTE, with a special focus on APE. Great attention has also been paid
to link current pathophysiological evidence with potential therapeutic implications.

2. miRNAs: Pathophysiological Actors and Potential Useful Biomarkers of Thromboembolism

miRNAs are noncoding RNAs around 22 nucleotides long [9] mainly involved in posttranslational messenger RNA (mRNAs) degradation [10]. miRNAs generate from gene exons—or less frequently introns—and processed into premiRNAs [11–13]. Once in the cytoplasm, pre-miRNAs are processed by a Dicer into mature miRNAs [14] that are released freely or within microvesicles. The way miRNAs are carried also has high relevance in their pathophysiology. Within microvesicles, miRNAs may complex and interact with other molecules, even those involved in thrombosis and homeostasis. Furthermore, microvesicle composition may provide information on the cellular source of miRNAs [15]. By targeting hundreds of genes [16], the spectrum of activity for each miRNAs broadly ranges from translation repression [17] to stimulation [18, 19], target degradation, and transcriptional/posttranscriptional gene silencing as well [20, 21]. The regulatory role of miRNAs is known since decades [22] but their applications as diagnostic/prognostic markers [23]—and even therapeutic targets [24]—have been only recently investigated. Many features would characterize miRNAs as ideal biomarkers: stability, low structural complexity, lack of postprocessing modifications, organ- and cell-specific expression, and tissue- and pathology-specific regulation [25–27]. miRNAs are also detectable in many fluids—e.g., such as serum, plasma, urine, and saliva [28]—where they regulate different biological processes [29, 30]. In light of these properties, miRNAs are being increasingly described as potential biomarkers of disease, including cardiovascular ones: heart failure, arrhythmias, coronary artery disease, myocardial fibrosis, and pulmonary arterial hypertension (PAH) [31, 32]. Although bioinformatics plays a big part in identifying putative miRNAs, a range of techniques has been developed to overcome technical challenges and simplifying miRNA profiling. Alongside quantitative PCR—characterized by high specificity and sensitivity but limited to small scale experiments—clinical application of miRNA assay relies on array or multiplex profiling, which maintain high sensitivity and specificity.

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Study design</th>
<th>miRNA (cut-off)</th>
<th>Sample</th>
<th>Results</th>
<th>Concerning</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mao et al. [63]</td>
<td>2011</td>
<td>32 APE patients vs. 32 healthy controls vs. 22 non-APE patients*</td>
<td>miRNA-134 (10-fold difference between miRNA levels)</td>
<td>Plasma</td>
<td>miRNA-134 was significantly higher in APE with an AUC of 0.83 (95% CI, 0.74 to 0.93) p &lt; 0.001</td>
<td>miRNA-134 was elevated also in UA</td>
</tr>
<tr>
<td>Hoekstra et al. [65]</td>
<td>2016</td>
<td>37 APE patients vs. 37 healthy controls</td>
<td>miRNA-28-3p (4-fold difference between miRNA levels)</td>
<td>Plasma</td>
<td>miRNA-28-3p (but neither miRNA-134 nor miRNA-210) show a significant increase—stable during the first 6 hours—in APE. The AUC was 0.79 (95% CI 0.69 to 0.90) miRNA-27a expression was upregulated in APE patients (p &lt; 0.001). The AUC was 0.78 (95% CI 0.69 to 0.88); p &lt; 0.001. miRNA-27a significantly improved the AUC of D-dimer</td>
<td>miRNA-27a levels are also influenced by LVH</td>
</tr>
<tr>
<td>Zhou et al. [66]</td>
<td>2018</td>
<td>78 APE patients vs. 70 healthy controls</td>
<td>miRNA-27a/b</td>
<td>Plasma</td>
<td>In acute state (1st day), miRNA-1233 was even able to discriminate APE from NSTEMI with an AUC of 0.95 (95% CI 0.89 to 1.00); p &lt; 0.001 highest serum level on 1st day. miRNA-1233 then decreased levels on 3rd and 5th day with lower values reached at 9 months</td>
<td>None. Even, miRNA-1233 was better than miRNA-134 and miRNA-27a as APE biomarker</td>
</tr>
<tr>
<td>Ba et al. [69]</td>
<td>2016</td>
<td>30 APE patients vs. NSTEMI (n = 30), DVT (n = 6), PAH (n = 15), and 12 healthy controls</td>
<td>miRNA-1233 (11-fold difference between miRNA levels)</td>
<td>Serum</td>
<td>miR-221 was significantly upregulated in APE (p &lt; 0.05) and showed positive correlations with BNP, troponin, and D-dimer. AUC for plasma miR-221 was 0.82 (95% CI 0.76 to 0.91), higher than that of D-dimer</td>
<td>miRNA-221 was elevated also in MI and PAH</td>
</tr>
<tr>
<td>Nie et al. [72]</td>
<td>2018</td>
<td>60 APE vs. 50 healthy controls</td>
<td>miRNA-221 (4-fold difference between miRNA levels)</td>
<td>Plasma</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

APE: acute pulmonary embolism; AUC: area under the curve; UA: unstable angina; DM: diabetes mellitus; GI: gastrointestinal; LVH: left ventricular hypertrophy; NSTEMI: non-ST elevated myocardial infarction; DVT: deep venous thrombosis; PAH: pulmonary arterial hypertension; BNP: B-type natriuretic peptide; MI: myocardial infarction.
alongside with a straightforward data analysis. Much more is expected from the incoming development of RNA sequencing that would perform whole-genome analysis.

2.1. The Role of miRNA on Hemostasis and Thrombosis. A growing body of evidence has identified for miRNAs an active role of hemostasis and thrombosis. This effect may be driven by an active modulation of specific proteins: factor XI, plasminogen activator inhibitor 1 (PAI-1), protein S, fibrinogen, tissue factor, and antithrombin [33, 34]. Due to their partial inheritance expression and susceptibility to environmental factors, miRNAs may then have a dynamic role in VTE, which would encompass the whole classical Virchow’s triad. Many of them have been then tested in clinical studies [35, 36], but a major role has been accounted for miR-145, miR-195, miR-483-3p, miR-532, and miR-1233 [37]. Among them, miR-145 is specific of vascular smooth muscle cells (VSMCs) and exerts regulatory properties on tissue factor (TF) gene expression. miR-145 expression is also inversely correlated proinflammatory cytokines and lower incidence of thrombosis [38, 39]. Specific miRNA signatures have been then associated to all stage of thrombotic process from initiation to organization, recanalization, and resolution. Endothelial progenitor cells (EPCs) exert a control on these processes [40]. Their suppression results in the overexpression of proinflammatory cytokines and inhibition of VEGF functions, hallmark of thrombotic risk, and associated with miR-195. GABA type A receptor-associated protein like 1 activation has been identified as the direct target by which miR-195 exerts its detrimental functions on cell proliferation, migration, angiogenesis, and autophagy [41].

The role of miRNAs on hemostasis and thrombosis is not only limited to the coagulation cascade but also involves platelet activation and reactivity [42, 43]. Increase in platelet reactivity has been associated with the overexpression of miR-320 family as consequence of the interaction with the WIPF1 gene encoding for WAS/WASL-interacting protein [44]. miR-423-5p is another biomarker of platelet aggregation [45]. Both miR-320 family and miR-423-5p may then raise susceptibility for VTE [46], whereas miR-1233 has been indicated as connecting signal between platelets and ECs [47].

Other miRNAs are finally implicated in vascular repair and thrombus resolution. This effect—mediated by angiogenesis and EPC proliferation/migration—involves miR-21, miR-126, miR-150, and miR-424 [48–51].

Although far from routinely clinical application, identifying those specific miRNA signatures—virtually targeting all Virchow’s triad [52]—would have a rationale for VTE risk stratification [53].

3. miRNAs in Acute Pulmonary Embolism: Experimental Data and Clinical Evidence

Despite the epidemiological and clinical relevance, diagnosis of APE still represents an unmet clinical need. D-dimer is routinely used as biomarker of APE but it is burdened by a
very low specificity [54]. Many other biomarkers tested in the last decades failed to replace or improve D-dimer performance [55–57]. Concerning miRNAs, experimental data are mainly focusing on vascular response to APE [58–63], while data on APE predictor/diagnosis are few. The lack of standardization their assay represents an additional confounder. However, all studies here considered share similar laboratory processes with differences in protocol of centrifugation (Table 1).

First in 2011, a panel of 30 different miRNAs was tested in a case control study matching patients with suspected APE [64]. Among the most expressed miRNAs (10-fold or higher), plasmatic miR-134 was the best predictor of APE, also able to identify high/intermediate vs. low-risk patients. miR-134 was then identified as specifically expressed by mononuclear blood cells [65] but its specificity for APE diagnosis was not later confirmed. Rather, a persistent increase (about 3.6-fold) in miR-28-3p was observed even hours after the onset of APE [66]. A release by hypoxic-ischemic lung cells as response to inositol phosphate metabolism and phosphatidylinositol pathway activation has been also hypothesized as mechanisms for the miR-28-3p expression. More recently, plasmatic concentrations of miR-27a and miR-27b emerged as further potential diagnostic markers of APE, being able to increase diagnostic potential of D-dimer [67]. Accordingly, the miR-27 family is known to regulate the TF pathway inhibitor (TFPI) in ECs [68, 69]. Platelet-derived miR-1233 is another candidate biomarker associated with suppressant activity on platelet activation and P-selectin expression [70]. Clinical relevance of miR-1233 relies on the ability in discriminating APE from other thrombotic disease (e.g., non-ST elevation myocardial infarction (NSTEMI) and DVT) with an early predictive value, higher than miRNA-27a and miRNA-134 [71]. Finally, more recent analysis on extensive miRNA panels identified a role for plasmatic miR-221, a VSMC-specific product upregulated by platelet-derived growth factor [72, 73]. Plasmatic miR-221 significantly increased in patients with APE a cut-off set at 4-fold overexpression [74]. The abovementioned studies provide the rationale but lacks of definitive proof for translating miRNA assay in clinical practice (Figure 1). Small sample size and bias involving patient selection and miRNA analysis protocol are likely their main weakness. Future studies are expected to address these issues performing real-life analyses and finally test whether miRNA assay may overcome D-dimer in diagnosing APE. To date, miRNA assay still remains far from any potential clinical translation.

4. Conclusion

The recognition of a circulating biomarker able to stratify the risk for APE would lead more accurately patients with clinical suspect of APE to second-level diagnostic tools, such as CTPA. This would be of paramount relevance for patients with mild/severe contraindications to CTPA, especially those with chronic kidney disease or history of medium contrast allergic reactions. Data from preliminary studies also suggest a potential role of miRNAs in discriminating APE from the most frequent confusing clinical conditions (firstly NSTEMI). Such an achievement would shorten the diagnostic chart and the time-to-treatment protocols, in accordance with the classic paradigm of “golden hour.” Even if it were, benefit of miRNA assay should also exceed the economic burden of their assay. The need of large panel assays and interaction analyses makes machine learning approach mandatory to finally establish the sensitivity of miRNA (as single biomarker or panel) and their clinical relevance. Additional goals should also include high sensitivity and specificity for APE. Comparing miRNAs with other biomarkers of APE (e.g., NT-proBNP, troponins, and D-dimer) would further help in establishing their potential for clinical use. Not last, being miRNA expression partially inherited, large-scale studies should consider different ethnic groups. Finally, any potential role of anticoagulation therapies on miRNA expression remains unclear.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This study was supported by a grant from the Rete Cardiologica of Italian Ministry of Health (#2754291) to Prof. F. Montecucco.

References

microRNAs: association with disease and potential use as biomarkers, 


